Baystreet Staff - Monday, October 6, 2014 Alcobra (ADHD) plummets on test results Alcobra (NASDAQ: ADHD) dropped 48.3% to $7.29 following the announcement of topline results from Phase III study of MDX in adult ADHD. Share volume was 652,000, more than 11 times its all-day average